Skip to main content

Tempus AI signals beyond the news: 69+ signals from 7 sources

The latest Tempus AI signal on this page is from Nov 17, 2026 (Patents): "TEMPUS AI, INC.'s patent output is steady: 24 grants in the past year, 2 in the past 30 days." The busiest sources: Glassdoor (15+), LinkedIn (15+) and Website changes (15+).

Public (TEM)Biotechnology Research5,001 to 10,000 employeestempus.comLinkedIn

Get Tempus AI's live signals in Claude or ChatGPT, or by API

AskWhat changed at Tempus AI this week? Use Autobound signals for tempus.com.
Signals
69+
Sources
7
Last 90 days
37
Latest
Nov 17, 2026

Source: Autobound Signal API · 97 signals tracked for Tempus AI · updated

Other signals · latest 10

Latest Tempus AI signals by source

69+ signals for Tempus AI across 7 sources.

  1. Patents · Patent pace

    TEMPUS AI, INC.'s patent output is steady: 24 grants in the past year, 2 in the past 30 days.

    Over the past year TEMPUS AI, INC. received 24 US patent grants, concentrated in health tech / medical informatics and software / computing; the recent pace (6 in 90 days) is steady versus its trailing baseline.

    Grants, 12 months
    24
    Grants, 90 days
    6
    Grants, 30 days
    2
    USPTO assignee
    Tempus AI, Inc.

    Google Patents

  2. LinkedIn

    Tempus AI launches Real-Time Variant Tracker as a supplement to xM NeXT Personal Dx.

    xM (NeXT Personal® Dx) is a key part of the patient care continuum, providing crucial information during surveillance and monitoring for early-stage disease and for IO treatment response monitoring for late-stage disease. Now available to support your clinical insights, Real-Time Variant Tracker™ is a supplemental...

    Likes
    71
    Comments
    0
    Tags
    Medical Research, Pharmaceuticals
    Initiatives
    launch of Real-Time Variant Tracker

    LinkedIn

  3. LinkedIn

    Tempus will present six abstracts at the CTOS Annual Meeting on rare mesenchymal tumors.

    Next week, Tempus will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society Annual Meeting (November 18–21). In rare diseases like sarcoma, small patient populations have historically created barriers to research. By leveraging our multimodal library, which includes...

    Likes
    60
    Comments
    1
    Tags
    Medical Research, Pharmaceuticals, Data Management
    Initiatives
    presenting six abstracts at CTOS meeting

    LinkedIn

  4. Patents · Patent grant

    Tempus AI was granted a patent for AI-based heart risk prediction.

    In November 2026 Tempus AI patented a clinical tool for estimating coronary blood-flow health and cardiac-event risk from ECGs and patient records.

    Patent title
    Predicting fractional flow reserve from electrocardiograms and patient records
    Grant date
    Nov 10, 2026
    Inventors
    Kipp Johnson, Tanner Carbonati

    Google Patents

  5. Glassdoor · Compensation dissatisfaction

    Employees report dissatisfaction with total compensation and lack of 401k matching program

    Multiple employees cite low salary levels and a lack of 401k matching as significant pain points in their compensation packages.

    Overall rating
    3.1 of 5
    CEO approval
    44%
    Reviews read
    7
    Review window
    Oct 20, 2026 to Nov 8, 2026

    Glassdoor

  6. Glassdoor · Growth opportunities

    Staff report limited career advancement paths outside of management tracks

    Employees describe an environment where promotion to higher technical levels is made unnecessarily difficult and career paths are poorly defined.

    Overall rating
    3.1 of 5
    CEO approval
    44%
    Reviews read
    7
    Review window
    Oct 20, 2026 to Nov 8, 2026

    Glassdoor

  7. Product reviews · Pricing concerns

    Verified User reports Tempus is expensive to use despite being cost-effective

    A Verified User in Computer & Network Security at a Small-Business company notes that Tempus is expensive to use, although they deem it cost-effective overall. This indicates a potential barrier for some users or a concern regarding the cost-to-value ratio.

    Star rating
    4 of 5
    Reviewer
    Verified User in Computer & Network Security
    Reviewer details
    Small-Business (50 or fewer emp.)

    g2.com

  8. Reddit · Acquisition announced

    Tempus has an agreed buyout offer to acquire Personalis at $16.25 per share, which is pending shareholder approval.

    Post: "PSNL - a textbook case of reflexivity from Soros’ Alchemy of Finance?"

    Subreddit
    r/wallstreetbets
    Upvotes
    1
    Comments
    0
    Sentiment
    Neutral

    r/wallstreetbets

  9. YouTube

    Tempus AI 60% Rocket! Buy TEM Stock Now! TEM Stock Analysis

    Ez Money Show analyzes Tempus AI stock, discussing its potential as a portfolio investment.

    Channel
    Ez Money Show
    Views
    23
    Comments
    0
    Tags
    Stock Analysis, Biotechnology, Precision Medicine

    YouTube (Ez Money Show)

  10. Website changes · Product launch

    No new products, services, or major feature launches are indicated in the recent website update.

    The content remains focused on existing solutions, clinical data, and integration capabilities without mention of new offerings.

    Page
    /oncology

    tempus.com

Showing 10 of 69+ signals. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Tempus AI with the Signal API

One POST /v1/companies/enrich call with tempus.com returns Tempus AI signals from 14 more signal types (reddit-company, podcast-company, glassdoor-company and more), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{
    "domain": "tempus.com",
    "signal_types": ["reddit-company","podcast-company","glassdoor-company",
      "product-reviews","linkedin-post-company","twitter-company-posts",
      "youtube-company","website-intelligence","patents-company",
      "federal-contract-award","conference-speaker","hackernews",
      "producthunt-launch","seo-traffic"],
    "limit": 20
  }'

Bulk data

Need these signals for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file).

Talk to sales

Same industry

Questions about Tempus AI other signals

What signals does Autobound track for Tempus AI besides news and filings?
This page lists 69+ signals for Tempus AI from 7 sources: Glassdoor (15+), LinkedIn (15+), Website changes (15+), YouTube (12), Patents (5), Reddit (4) and Product reviews (3). Every row is dated, and most link to the post, review or record.
What are people saying about Tempus AI online?
The newest posts on this page: Aug 28, 2026, Reddit (r/wallstreetbets): Tempus has an agreed buyout offer to acquire Personalis at $16.25 per share, which is pending shareholder approval. Aug 28, 2026, Reddit (r/Stoxcraft): Tempus AI agreed to acquire genomic sequencing company Personalis for roughly $1.5B. Aug 24, 2026, Reddit (r/StockTitan): Tempus received FDA clearance for its AI product designed to detect signs of pulmonary hypertension from standard ECGs.
What do employees say about working at Tempus AI?
The newest Glassdoor theme on this page, dated Nov 8, 2026: Employees report dissatisfaction with total compensation and lack of 401k matching program. The overall rating in that row is 3.1 of 5. Themes summarize recent reviews; read the reviews on Glassdoor for the full picture.
Has Tempus AI been granted patents recently?
Yes. The newest grant on this page: Nov 10, 2026, Patents (Google Patents): Tempus AI was granted a patent for AI-based heart risk prediction.

Page updated , the date of the newest row on this page.

Source. Reddit, podcasts, Glassdoor, product reviews, LinkedIn, X, YouTube, company websites, patents, federal contracts, conference talks, Hacker News, Product Hunt, web traffic and employee growth, from the Signal API.

Method. The latest 15 signals per source from the last 12 months. Posts that do not name the company, replies, repeats and unreadable rows are removed. Traffic and headcount keep their newest measure.

Data as of .

How this data is built →Get it from the Signal API →